Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Entresto US Sales Barriers Set To Be Removed By Strong Guidance

Executive Summary

Sales prospects for Novartis AG's struggling Entresto have been boosted – especially in the US – by new global cardiology guidelines issued by three organizations containing stronger than expected recommendations for its use in treating heart failure.

Advertisement

Related Content

Novartis's Entresto Voyage: Hindsight Is 20/20
Novartis Woos Payers With Data Showing Entresto Earns Its Keep
Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No
Novartis's Entresto Doesn't Impress In 1Q; Orphan Drug Fails In PhIII

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

SC065254

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel